{"id":3408,"date":"2026-09-23T09:00:00","date_gmt":"2026-09-23T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3408"},"modified":"2026-09-23T20:00:41","modified_gmt":"2026-09-24T00:00:41","slug":"modified-guide-rna-boosts-liver-prime-editing","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3408","title":{"rendered":"Modified Guide RNA Boosts Liver Prime Editing"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Wuhan University (Academic)<\/p>\n

Event Type<\/strong><\/p>\n

Peer-Reviewed Preclinical Publication (Publication Catch-Up)<\/p>\n

Modality<\/strong><\/p>\n

Prime Editing (Modified pegRNA)<\/p>\n

Asset<\/strong><\/p>\n

Motif-Modified pegRNA \/ Prime Editor mRNA-LNP<\/p>\n

Target<\/strong><\/p>\n

Undisclosed (Liver-Expressed Target Protein)<\/p>\n

Disease Area<\/strong><\/p>\n

Platform Technology (Liver-Directed Gene Editing)<\/p>\n

Summary<\/h4>\n

A Wuhan University-led peer-reviewed study published online 11 September in Nature Biomedical Engineering reports nearly 70 percent prime editing of bulk mouse liver after one systemic lipid nanoparticle dose carrying prime editor RNA and densely motif-modified pegRNAs. At a dose described by the authors as clinically translatable, target protein suppression followed editing, with nearly 80-fold greater editing than conventional end-modified pegRNAs. Human translation, genome-wide fidelity and disease benefit have not been established.<\/p>\n

The team engineered dense chemical modification within RNA motifs, including MS2, to improve pegRNA performance. The authors also reported enhancement across other split RNA-guided editing systems, including up to 11-fold higher base editing efficiency in studied conditions. The work is peer reviewed and China originated, with an 11 September online publication date distinct from later indexing.<\/p>\n

Results are in mouse liver. The abstract does not provide a clinical trial, validated extrahepatic delivery, human dosing, long-term genotoxicity assessment or therapeutic correction in a patient population. The strong liver editing fraction is not evidence that every hepatocyte or disease allele can be corrected at the same rate.<\/p>\n

Deep Analysis<\/h4>\n

Interpretation one is that chemical stabilization and architecture of pegRNA can remove a major efficiency bottleneck for transient nonviral prime editing. A single LNP dose and large relative gain support this. Against it, performance is target-, sequence-, dose- and tissue-dependent; comparison to a low-performing guide can inflate fold gain.<\/p>\n

Interpretation two is that the motif modification is a general platform applicable to base and other editing tools. Broad in vitro tests provide support, but off-target edits, unintended reverse transcription products, large genomic rearrangements, innate immune activation and batch reproducibility need rigorous evaluation in vivo. Hepatocyte access does not imply marrow, muscle or CNS delivery.<\/p>\n

Upgrade evidence includes multiple disease-relevant loci with absolute editing and phenotypic rescue at tolerable doses, genome-wide and RNA off-target profiling, primate biodistribution and manufacturing reproducibility. Failure to replicate across guides or unsafe genomic byproducts would falsify a broad therapeutic platform claim.<\/p>\n

Company and Product Background<\/h4>\n

Prime editing uses a Cas nickase fused to a reverse transcriptase and a pegRNA that both targets DNA and templates a defined sequence change. Its programmable scope extends beyond some base editor substitutions, but pegRNA stability and effective delivery can limit in vivo performance. LNPs are well suited to liver exposure but less proven for bone marrow or other tissues. The authors are affiliated with Wuhan University and a Shanghai gene editing center.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Evidence class: peer-reviewed preclinical study; online 11 September 2026.<\/li>\n
  • Mouse liver: nearly 70 percent bulk prime editing after one systemic LNP dose.<\/li>\n
  • Relative gain: nearly 80-fold versus conventional end-modified pegRNA in reported comparison.<\/li>\n
  • Other editors: up to 11-fold base-editing increase in tested systems.<\/li>\n
  • Unresolved: primate efficacy, off-target and genotoxicity, immune response and tissue reach.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The high absolute mouse liver editing rate makes this a material chemistry and delivery advance. Inference: chemically optimized guides may broaden the practical range of transient prime editing. It should remain an uncertain translational signal until multiple loci and larger-animal studies establish potency and safety at human-relevant exposures.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: uncertain for therapeutic translation. Confidence in Facts: high for the published experimental claims. Confidence in Interpretation: low-moderate because evidence is preclinical, chiefly mouse liver, with limited accessible full-text safety detail.<\/p>\n","protected":false},"excerpt":{"rendered":"

    A Wuhan University-led peer-reviewed study published online 11 September in Nature Biomedical Engineering reports nearly 70 percent prime editing of bulk mouse liver after one systemic lipid nanoparticle dose carrying prime editor RNA and…<\/p>\n","protected":false},"author":1,"featured_media":3410,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[369,462,855],"class_list":["post-3408","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-gene-editing","tag-prime-editing","tag-wuhan-university"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3408"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3408\/revisions"}],"predecessor-version":[{"id":3421,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3408\/revisions\/3421"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3410"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}